Related Experiment Video

Updated: Jul 15, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

Cardiac myosin-binding protein C in community-based patients with suspected heart failure

Kieran F Docherty1, Mark C Petrie1, Gemma McKinley2

  • 1BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland G12 8TA, UK.

European Journal of Heart Failure
|July 14, 2026
PubMed

Insights

Adding cardiac myosin-binding protein C (cMyBP-C) to NT-proBNP testing improves heart failure (HF) diagnosis, particularly for HF with reduced ejection fraction (HFrEF). This biomarker combination aids in prioritizing echocardiography for suspected HF patients.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Heart Failure Diagnostics

Background:

  • Myocardial injury is a key indicator of heart failure (HF).
  • The added diagnostic value of novel myocardial injury biomarkers, such as cardiac myosin-binding protein C (cMyBP-C), beyond natriuretic peptides in community patients with suspected HF remains unclear.

Purpose of the Study:

  • To investigate the additive diagnostic value of established and novel myocardial injury biomarkers compared to natriuretic peptides in community patients with suspected HF.
  • To assess the diagnostic accuracy of NT-proBNP, hs-cTnT, and cMyBP-C alone and in combination for HF detection and classification.

Main Methods:

  • A multicentre, prospective, observational study involving community patients with suspected HF and elevated NT-proBNP.
  • Measurement of NT-proBNP, high-sensitivity cardiac troponin T (hs-cTnT), and cardiac myosin-binding protein C (cMyBP-C) from venous blood samples.
  • Diagnostic accuracy evaluated using the area under the receiver operating characteristic curve (AUROC) for HF and HFrEF detection.

Main Results:

  • The combination of NT-proBNP and cMyBP-C demonstrated the highest AUROC (0.77) for diagnosing HF versus no HF, outperforming NT-proBNP alone (0.74).
  • For detecting HF with reduced ejection fraction (HFrEF), the NT-proBNP and cMyBP-C combination yielded an AUROC of 0.90, compared to 0.85 for NT-proBNP alone.
  • NT-proBNP, hs-cTnT, and cMyBP-C levels were highest in patients with HFrEF.

Conclusions:

  • Cardiac myosin-binding protein C (cMyBP-C) measurement enhances the diagnostic accuracy of NT-proBNP in patients with suspected heart failure.
  • The addition of cMyBP-C provides significant value in identifying HFrEF.
  • This biomarker combination may assist in prioritizing echocardiography for patients with suspected HF.
Abstract

Keywords:
BiomarkersDiagnosisHeart failureNatriuretic peptidesTroponin

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...